文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒性休克非存活者补充左卡尼汀后酰基肉碱持续升高

Septic Shock Nonsurvivors Have Persistently Elevated Acylcarnitines Following Carnitine Supplementation.
PubMed 文献 · Shock · 2018-01-01
一句话结论脓毒性休克患者补充左卡尼汀后多种酰基肉碱升高并持续至少36小时,非存活者升高更明显,提示其代谢紊乱更重。

该研究检测了参加随机对照试验的脓毒性休克患者血清样本,左卡尼汀组16例、安慰剂组15例,在入组时(T0)、输注完成后12小时(T24)及入组后48小时(T48)测定酰基肉碱、游离脂肪酸和胰岛素。1年死亡率左卡尼汀组为8/16(50%),安慰剂组为12/15(80%)。入组时非存活者的游离肉碱、C2、C3和C8酰基肉碱较高;左卡尼汀治疗使所有测定的酰基肉碱升高,效应在输注完成后持续至少36小时,且在非存活者中更明显。葡萄糖、乳酸和胰岛素水平未因生存状态或治疗分组而不同。

要点

  • 脓毒性休克患者1年死亡率:左卡尼汀组8/16(50%),安慰剂组12/15(80%)。
  • 入组时非存活者的游离肉碱、C2、C3和C8酰基肉碱高于存活者。
  • 左卡尼汀治疗使所有测定的酰基肉碱升高,效应在输注完成后持续至少36小时。
  • 左卡尼汀引起的酰基肉碱升高在非存活者中更明显。
  • 葡萄糖、乳酸和胰岛素水平未因生存状态或治疗分组而不同。

适用人群与场景

  • 参加随机对照试验的脓毒性休克患者,左卡尼汀组16例、安慰剂组15例。

处置流程与药物剂量

  • 左卡尼汀组给予左卡尼汀,安慰剂组给予安慰剂;在入组时(T0)、输注完成后12小时(T24)及入组后48小时(T48)采集血清样本检测酰基肉碱、游离脂肪酸和胰岛素。

研究设计与关键结果

  • 研究类型:随机对照试验的二次分析;样本量31例(左卡尼汀组16例、安慰剂组15例);人群为脓毒性休克患者。
  • 1年死亡率:左卡尼汀组8/16(50%),安慰剂组12/15(80%)。
  • 入组时非存活者的游离肉碱、C2、C3和C8酰基肉碱高于存活者。
  • 左卡尼汀治疗使所有测定的酰基肉碱升高,效应在输注完成后持续至少36小时,且在非存活者中更明显。
  • 部分游离脂肪酸呈现相似但不太一致的模式。
  • 葡萄糖、乳酸和胰岛素水平未因生存状态或治疗分组而不同。

证据类型、等级与局限

  • 证据类型:随机对照试验的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,非存活者对左卡尼汀表现出与存活者不同的代谢反应,可能提示存在预先存在或更严重的代谢紊乱,限制了任何治疗获益反应。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Sepsis-induced metabolic disturbances include hyperlactatemia, disruption of glycolysis, protein catabolism, and altered fatty acid metabolism. It may also lower serum L-carnitine that supports the use of L-carnitine supplementation as a treatment to ameliorate several of these metabolic consequences.

METHODS: To further understand the association between L-carnitine-induced changes in serum acylcarnitines, fatty acid metabolism and survival, serum samples from (T0), 12 hfollowing completion (T24) of L-carnitine (n = 16) or placebo (n = 15) administration, and 48 h (T48) after enrollment from patients with septic shock enrolled in a randomized control trial were assayed for acylcarnitines, free fatty acids, and insulin. Data were analyzed comparing 1-year survivors and nonsurvivors within treatment groups.

RESULTS: Mortality was 8 of 16 (50%) and 12 of 15 (80%) at 1 year for L-carnitine and placebo-treated patients, respectively. Free carnitine, C2, C3, and C8 acylcarnitines were higher among nonsurvivors at enrollment. L-Carnitine treatment increased levels of all measured acylcarnitines; an effect that was sustained for at least 36 h following completion of the infusion and was more prominent among nonsurvivors. Several fatty acids followed a similar, though less consistent pattern. Glucose, lactate, and insulin levels did not differ based on survival or treatment arm.

CONCLUSIONS: In human patients with septic shock, L-Carnitine supplementation increases a broad range of acylcarnitine concentrations that persist after cessation of infusion, demonstrating both immediate and sustained effects on the serum metabolome. Nonsurvivors demonstrate a distinct metabolic response to L-carnitine compared with survivors, which may indicate preexisting or more profound metabolic derangement that constrains any beneficial response to treatment.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Puskarich MA, Evans CR, Karnovsky A, et al. Septic Shock Nonsurvivors Have Persistently Elevated Acylcarnitines Following Carnitine Supplementation. Shock. 2018. PMID: 29384504. doi:10.1097/SHK.0000000000000997

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。